Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Combination of radiotherapy and anti-hormone treatment can prevent recurrence of hormone-driven breast cancer

Women with early, low risk, hormone-driven breast cancer are less likely to have a recurrence of their disease if they have radiotherapy after surgery, as well as anti-hormone treatment, according to results from a trial that has followed 869 women for ten years.

26 Apr 2019

Partner status influences link between sexual problems and self-efficacy in breast cancer survivors

Vaginal dryness and painful intercourse are some of the more common adverse events of post-breast cancer treatment therapies and often lead to sexual dissatisfaction and an overall lower quality of life.

17 Apr 2019

Molecular patterns could help predict relapse risk in breast cancer patients

The genetic and molecular make-up of individual breast tumors holds clues to how a woman’s disease could progress, including the likelihood of it coming back after treatment, and in what time frame, according to a Cancer Research UK-funded study published in Nature today (Wednesday).

14 Mar 2019

Estrogen can affect surrounding brain cells to promote triple-negative breast cancer metastasis

Triple-negative breast cancers are more likely than other breast cancer types to metastasize and are especially likely to go the brain in younger women. Researchers have tested various hypotheses to explain this danger.

2 Mar 2019

Researchers unravel path of metallodrug in a breast cancer cell

Some types of cancer cannot be treated with classical chemotherapy. Scientists from Inserm, CNRS, Sorbonne University, PSL university, University Grenoble Alpes and ESRF, the European Synchrotron, are working on a metallorganic molecule as an antitumor drug.

4 Feb 2019

Scientists create comprehensive new method to predict breast cancer risk

Scientists have created the most comprehensive method yet to predict a woman's risk of breast cancer, according to a study by Cancer Research UK published in Genetics in Medicine.

14 Jan 2019

MUSC researchers link higher levels of AGEs to ER-positive breast cancer risk

Poor diet and lack of exercise are associated with cancer development, but the underlying biology is not well understood. Advanced glycation end products could offer a biological link to help us understand how certain lifestyle behaviors increase cancer risk or lessen the likelihood that an anti-cancer therapy will be effective.

28 Dec 2018

New substance could improve efficacy of established breast cancer treatments

Physicians from Karl Landsteiner University of Health Sciences in Krems (Austria) demonstrate potential for clinical application, collaborating with research groups from Germany, the USA, and China.

13 Dec 2018

Study: Drug reduces hot flash frequency, improves quality of life in breast cancer survivors

Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors.

7 Dec 2018

Women consider potential harms and benefits of using preventive therapy for breast cancer

Only around a fifth of women at higher risk of developing breast cancer think they need to take a drug proven to help prevent the disease, according to new research funded by Cancer Research UK and published today (Monday) in Clinical Breast Cancer.

2 Dec 2018

Researchers identify molecule to fight myotubular myopathy

Myotubular myopathy is a severe genetic disease that leads to muscle paralysis from birth and results in death before two years of age. Although no treatment currently exists, researchers from the University of Geneva, Switzerland, - working in collaboration with the University of Strasbourg, France, - have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven.

19 Nov 2018

New model of FSHD could be useful to study effectiveness of experimental therapeutics

Facioscapulohumeral muscular dystrophy is the most prevalent dominantly inherited muscular dystrophy in the world. To date, there are no pharmacologic treatments available for the more than 850,000 people affected worldwide.

17 Nov 2018

Radiation therapy can lower risk of breast cancer recurrence in patients with ‘good risk’ DCIS

A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report.

30 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients

Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018.

19 Oct 2018

Tamoxifen News and Research

Further Reading